Brinker Capital Investments, LLC Neurocrine Biosciences Inc Transaction History

Brinker Capital Investments, LLC

$5.01 Billion
Q4 2022

A detailed history of Brinker Capital Investments, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 32,872 shares of NBIX stock, worth $4.85 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

32,872

Previous 35,160 6.51%

Holding current value

$4.85 Million

Previous $3.73 Million 5.14%

% of portfolio

0.08%

Previous 0.08%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$106.72 - $127.06 $244,175 - $290,713	-2,288 Reduced 6.51%	32,872 $3.93 Million
Q3 2022 Nov 01, 2022	BUY	$92.03 - $107.81 $146,051 - $171,094	1,587 Added 4.73%	35,160 $3.73 Million
Q2 2022 Jul 18, 2022	BUY	$75.79 - $100.07 $7,503 - $9,906	99 Added 0.3%	33,573 $3.27 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $466,143 - $610,007	6,434 Added 23.79%	33,474 $3.14 Million
Q4 2021 Feb 08, 2022	SELL	$79.65 - $106.22 $384,470 - $512,723	-4,827 Reduced 15.15%	27,040 $2.3 Million

Q2 2021 Aug 03, 2021	BUY	$89.43 - $102.27 $1.86 Million - $2.13 Million	20,789 Added 187.66%	31,867 $3.1 Million
Q1 2021 May 12, 2021	SELL	$87.57 - $119.4 $3.84 Million - $5.24 Million	-43,886 Reduced 79.84%	11,078 $1.08 Million
Q4 2020 Feb 16, 2021	BUY	$86.91 - $108.33 $2.57 Million - $3.2 Million	29,579 Added 116.52%	54,964 $5.27 Million
Q3 2020 Dec 03, 2020	BUY	$96.16 - $135.15 $2.44 Million - $3.43 Million	25,385 New	25,385 $2.44 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

94.5M

Call Options Held

505K

Put Options Held

341K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.

Account

Brinker Capital Investments, LLC Neurocrine Biosciences Inc Transaction History